New immunotherapy combo may let older colorectal cancer patients skip surgery
NCT ID NCT06205836
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether immunotherapy drugs (cemiplimab alone or with fianlimab) can shrink or eliminate tumors in older patients (70+) or those unfit for surgery with a specific genetic type of colorectal cancer (MSI-H). The goal is to avoid surgery if the cancer disappears completely on scans and endoscopy. Participants will be monitored for 24 months, and the study tracks both how well the treatment works and any serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Johns Hopkins SKCCC
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?